MAT-Pure therapy is administered via intravenous (IV) or subcutaneous (SC) injection of the macrophage-activating factor derived from the original Gc protein. Treatment is typically given once per week, or as directed by a qualified healthcare provider.
All applications must follow strict aseptic and sterile handling to ensure safety and preserve the integrity of the product. The administration process should only be performed by trained medical professionals familiar with proper injection techniques and immunotherapy procedures
The dosage and frequency of MAT-Pure administration are determined individually by the treating physician, based on each patient’s condition, immune status, and therapeutic response.
Because MAT-Pure is a natural immune activator, no strict upper dose limit has been established — allowing physicians to adjust the dosage as needed. This flexibility ensures that the treatment is both personalized and adaptable to the progression of each patient’s condition.
For patients diagnosed with cancer, HIV/AIDS, hepatitis, or tuberculosis, the recommended regimen is:
High-dose MAT-Pure (3.0 ml) administered once per week
Duration: 10 weeks (10 doses) per course
For advanced cases, treatment may be increased to two doses per week
Additional treatment courses may be required depending on disease progression and individual recovery. For chronic or advanced illnesses, physicians may recommend an extended or maintenance plan to ensure long-term immune support.
Macrophage activation is essential for immune defense and healing. Continuing MAT-Pure therapy as long as the disease is active helps the immune system identify and eliminate cancer cells, viruses, bacteria, and other pathogens.
Patients often report noticeable improvements within the first 6–8 weeks of therapy. However, the duration may vary based on overall health and immune resilience. After active treatment, maintenance dosing may be continued to stabilize immune function and prevent relapse.
Note: These dosage recommendations apply exclusively to IMMI MAT-Pure formulations.
For individuals with Autism Spectrum Disorders (ASD), MAT-Pure therapy aims to support immune balance and reduce inflammation that may contribute to neurological symptoms.
Recommended protocol:
3.0 ml High-Dose MAT-Pure, administered once weekly via subcutaneous injection
Minimum course: 10 weeks
Improvements are often seen within the first 2 months
As with other conditions, the treatment plan is personalized and may be extended depending on patient progress. Many individuals benefit from long-term maintenance doses to sustain immune health and neurological stability.
For ASD, we recommend a customized therapy plan designed in collaboration with a healthcare professional experienced in immunomodulatory treatments.
Note: These dosage guidelines apply only to IMMI MAT-Pure.
Take the first step toward a stronger, more resilient immune system with MAT-Pure.
Contact our specialists today to receive a personalized consultation and start your journey toward restored health and vitality.